Optima Health (OPT) Q4 2026 TU earnings summary

Executive summary

• Reported full-year revenue of approximately £121 million, reflecting 15% year-on-year growth and meeting market expectations.

• Adjusted EBITDA for FY26 expected to be about 10% ahead of previous market expectations.

• Completed a transformational £100 million acquisition of PAM Healthcare Limited in March 2026, enhancing scale and capabilities.

• Integration of PAM is progressing, with £1.3 million in annualised cost synergies already delivered by June 2026.

• New business annualised wins reached £10.8 million in FY26, with a strong pipeline for the enlarged group.

Financial highlights

• Revenue for the year ended 31 March 2026 was approximately £121 million, up from £105 million in FY25.

• Other income of £4.7 million recognised from a previously disclosed procurement matter.

• Net debt (excluding leases) stood at £94.4 million as of 31 March 2026, with a cash balance of £21.6 million and £116 million in debt.

• Net debt reduced at the end of May after repaying a £30 million shareholder bridging loan using proceeds from an equity raise.

Outlook and guidance

• Strategic objectives remain focused on achieving annual revenues of £200 million and £40 million of adjusted EBITDA in the medium term.

• Integration of PAM expected to deliver significant revenue synergies and operational efficiencies.

• Full year results for FY26 will be reported in August 2026.